<DOC>
	<DOCNO>NCT00872274</DOCNO>
	<brief_summary>To access single-dose oral bioequivalence sumatriptan succinate 100 mg tablet ( contain 140 mg sumatriptan succinate equivalent 100 mg sumatriptan ) OHM Laboratories Inc. ( subsidiary Ranbaxy Pharmaceutical Inc. USA ) IMITREX® 100 mg tablet ( contain 140 mg sumatriptan succinate equivalent 100 mg sumatriptan ) GlaxoSmithKline healthy , adult , male , human subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Sumatriptan 100mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomize two-treatment , two-period , two-sequence , single-dose , crossover bioequivalence study compare sumatriptan succinate tablet 100 mg ( contain sumatriptan succinate equivalent 100 mg sumatriptan ) manufacture OHM Laboratories Inc. IMITREX® 100 mg tablet ( contain sumatriptan succinate equivalent 100 mg sumatriptan ) manufacture GlaxoSmithKline Research Triangle Park NC 27709 , Made Canada healthy , adult , male , human , subject feed condition . Following overnight fast least 10 hour , single oral dose sumatriptan succinate tablet 100 mg either test reference formulation administer period study , along 240 mL drink water ambient temperature supervision train study personnel 30 min start high fat high calorie breakfast . Thirty-two 32 subject enrol study . Twenty-four ( 24 ) subject complete period study . Pharmacokinetic statistical analysis perform data 24 subject complete period study .</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>1 . Were age range 1845 year . 2 . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Had voluntarily give write informed consent participate study . 4 . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . 5 . Had nonvegetarian diet habit . 1 . Hypersensitivity Sumatriptan relate group drug drug . 2 . History interment chest pain chest tightness might might require medication relieve . 3 . History headache , vertigo , dizziness without nausea vomit 4 . History intermittent loss vision 5 . History seizure head injury . 6 . History peripheral vascular disease ( cramp , tiredness severe pain walk relatively short distance persist rest , noticeable change color ( blueness paleness ) temperature ( coolness ) compare limb ) 7 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 8 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma , headinjury coma . 9 . History psychiatric illness , might impair ability provide write informed consent . 10 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 11 . Presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . 12 . Positive urinary screen test drug abuse ( opiates cannabinoids ) 13 . Presence value , significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 14 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 15 . Clinically abnormal ECG Chest Xray . 16 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 17 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . 18 . Use enzyme modifying drug within 30 day prior Day 1 study . 19 . Participation clinical trial within 12 week precede Day 1 study . 20 . Subjects , completion study , would donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>